Syndax Pharmaceuticals Inc SNDX 深 滬
等待開盤 11-04 09:30:00 美东时间
14.29
+1.190
+9.08%
華盛通- 最 高14.485
- 今 開13.08
- 成交量 497.54万股
- 最 低 13.06
- 昨 收 13.10
- 總市值 12.76亿
- 52周最高 25.59
- 市盈率 靜 --
- 換手率 5.57%
- 52周最低 12.795
- 委 比 36.85%
- 總股本 8929.71万
- 歷史最高 29.86
- 量 比 1.55
- 振 幅 10.88%
- 歷史最低 3.39
- 每 手 1
- 風險率 2.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Apple To $350? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BTIG raised the price target for Tempus AI Inc (NASDAQ:TEM) from $80 to $100. BTIG analyst Mark Massaro mainta...
11-03 21:43
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $36
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $38 to $36.
11-03 19:33
Syndax Pharmaceuticals Q3 EPS $(0.55) Misses $(0.49) Estimate, Sales $83.298M Beat $81.850M Estimate
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.49) by 12.24 percent. This is a 21.43 percent increase over losses of $(0.70) per share from the same period last year. The company reported quarterly sales of $83.2...
11-03 05:01
Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer
Syndax Pharmaceuticals announced the retirement of CFO Keith A. Goldan and the appointment of Aaron A. Ondrey as the new CFO. Goldan, who played a key role in the successful launches of Revuforj and Niktimvo, will remain with the company through year-end to support the transition. Ondrey brings over 25 years of financial and operational leadership experience in the biotechnology industry.
11-02 21:01
Syndax Announces Participation in November Investor Conferences
Syndax Pharmaceuticals announced that CEO Michael A. Metzger and the management team will participate in four upcoming investor conferences: the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 10, the Stifel 2026 Healthcare Conference in New York on November 12, the UBS Global Biopharma Conference in London on November 17, and the Jefferies London Healthcare Conference in London on November 19. Fireside chats from the...
10-30 11:00
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026
Syndax Pharmaceuticals announced it will report its third quarter 2026 financial results and provide a business update on November 2, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET on the same day. The webcast and slides can be accessed via the company's website or through the provided dial-in numbers and webcast link. A replay will be available on the Investors section of the website within 24 hours and will ...
10-26 11:00
Syndax Pharmaceuticals Suffers Pipeline Blow
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) announced it will halt the clinical development of axatilimab in idiopathic pulmonary fibrosis (IPF) after the drug missed its primary endpoint in the Phase 2 MAXPIRe trial. The study failed to demonstrate efficacy in reducing the annualized rate of decline ...
10-14 00:24
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $38 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $38 price target.
10-13 18:59
美股夜盘 | Syndax Pharmaceuticals Inc暴泻15.59%，最新股价13.97美元
Syndax Pharmaceuticals Inc急泻15.59%，报13.97美元
10-13 09:44
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
Syndax Pharmaceuticals announced that the Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of reducing the annualized rate of forced vital capacity (FVC) decline. While axatilimab was well-tolerated with a safety profile similar to placebo, Syndax will not pursue further development of axatilimab in IPF. The drug continues to be studied in trials for chronic graft-versus-host disease (cG...
10-12 20:01
